Selective Growth Hormone Secretagogue
Ipamorelin 10mg is a synthetic pentapeptide studied at the growth-hormone secretagogue receptor, also called the ghrelin receptor. This 10mg vial is supplied for in-vitro research only. It has no product-specific LabDoc report; see the Quality page for available documentation. In-stock orders receive same-day dispatch from Victoria after payment confirmation, with tracked Australia Post Express shipping Australia-wide.
This product is sold strictly for in-vitro laboratory research purposes only. It is not a therapeutic good, is not approved by the TGA, and is not intended for human or animal consumption, injection, or any diagnostic or therapeutic use.
Synthetic pentapeptide · ghrelin-receptor research
Ipamorelin is a synthetic five-building-block peptide studied as a growth-hormone secretagogue: it prompts release of growth hormone rather than supplying growth hormone itself. Its research target is the growth-hormone secretagogue receptor (GHSR), also known as the ghrelin receptor. Early cell and preclinical work measured growth-hormone release through a GHRP-like receptor pathway, while a small healthy-volunteer infusion study measured a short growth-hormone response. This page separates those findings from claims about muscle, recovery, sleep or fat loss, which the reviewed human studies did not test as long-term outcomes. Each vial is labelled 10mg and 99% Purity. Peak Peptides Australia supplies this material for in-vitro research only, not for use outside laboratory research.
Also referred to in research or catalogue references as Ipamorelin, ipamorelin peptide, Ipamorelin 10mg, Ipamorelin 10 mg, NNC-26-0161, NNC 26-0161, 170851-70-4, GHRP-like secretagogue.
Ipamorelin is a pentapeptide: a short chain of five chemical building blocks. PubChem records its formula as C38H49N9O5, molecular weight as 711.9 g/mol, CAS number as 170851-70-4, and sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2.
Ipamorelin is researched as a growth-hormone secretagogue at the GHSR, often called the ghrelin receptor. In the foundational pharmacology paper, it stimulated growth-hormone release through a GHRP-like receptor pathway. It is not growth hormone and it is not a GHRH analogue.
The 1998 study compared Ipamorelin with GHRP-6 and GHRP-2. In its swine experiments, Ipamorelin did not raise ACTH or cortisol significantly above the response to GHRH stimulation, while GHRP-6 and GHRP-2 did. That is a controlled preclinical finding.
In a 1999 pharmacokinetic study, healthy male volunteers received a 15-minute intravenous infusion. Researchers estimated a terminal half-life of 2 hours and saw one brief episode of growth-hormone release, peaking at 0.67 hours. This finding describes that supervised infusion setting.
A multicentre Phase 2 trial enrolled 117 people after bowel resection and compared intravenous Ipamorelin with placebo. The median time to a tolerated solid meal was numerically shorter in the Ipamorelin group, but the study found no statistically significant difference in its primary or secondary efficacy analyses.
The 10mg label is the total amount recorded for this vial before liquid is added. If 3 mL of BAC water is added, the concentration is about 3.33 mg/mL. On a U-100 syringe, 1 unit is 0.01 mL, which holds about 0.033 mg or 33 mcg at that concentration.
This Ipamorelin 10mg listing has no product-specific LabDoc verification report. The vial label says 99% Purity. Muscle Blend Janoshik COA #135350 covers the separate blend.
Ipamorelin is not an FDA-approved medicine, and it is not an approved medicine in Australia. The 2026 WADA Prohibited List names Ipamorelin among growth-hormone secretagogues prohibited at all times in sport.
Ipamorelin is a synthetic pentapeptide. “Penta” means five, so the molecule has five linked chemical building blocks rather than the long chain found in a protein. PubChem records the sequence as Aib-His-D-2-Nal-D-Phe-Lys-NH2, the formula as C38H49N9O5 and the molecular weight as 711.9 g/mol.
It is researched as a growth-hormone secretagogue. That phrase means a compound that prompts a growth-hormone-release signal; it is not growth hormone itself. The central research target is GHSR, the growth-hormone secretagogue receptor, which is also called the ghrelin receptor.
Each Peak Peptides Australia vial is labelled IPAMORELIN, 10 mg and 99% Purity. The 10mg figure is the total labelled amount in the dry vial. It becomes a concentration only after a known volume has been added. This material is supplied for in-vitro research only.
Ipamorelin is studied at the GHSR or ghrelin-receptor pathway. In the 1998 pharmacology paper, GHRP and GHRH antagonists helped show that Ipamorelin, like GHRP-6, stimulated growth-hormone release through a GHRP-like receptor. This is different from a GHRH analogue such as Sermorelin or CJC-1295 NO DAC.
The first step is receptor signalling. The next measured endpoint in the early studies was growth hormone released from pituitary cells or into blood. Those are biological measurements, not direct measurements of muscle size, strength, sleep, recovery, fat loss or longevity.
The word “selective” comes from the 1998 comparison. In swine, Ipamorelin did not raise ACTH or cortisol significantly above the response seen with GHRH stimulation, unlike the GHRP-6 and GHRP-2 comparators. It describes that tested model and does not transfer a safety result to this individual vial.
The evidence begins with cell and preclinical pharmacology. Raun and colleagues reported that Ipamorelin released growth hormone from primary rat pituitary cells with potency and efficacy comparable with GHRP-6. Their swine work reported no significant ACTH or cortisol rise versus GHRH stimulation, which is the source of the early selectivity description.
A later pharmacokinetic and pharmacodynamic study involved eight healthy men at each of five intravenous infusion levels. It estimated a 2-hour terminal half-life. Growth hormone rose as a single episode, peaked at 0.67 hours and declined to negligible concentrations. The study measured short-term hormone pharmacology under supervised conditions.
The Phase 2 postoperative-ileus study asked a different question: whether ghrelin-receptor agonism changed bowel recovery after surgery. It enrolled 117 people, with 114 in the safety and modified intention-to-treat populations. Median time to a first tolerated solid meal was 25.3 hours with Ipamorelin and 32.6 hours with placebo, but the p value was 0.15 and the study did not show significant primary or secondary efficacy results.
| Study | What was measured | Finding |
|---|---|---|
| Raun et al., 1998 | Pituitary-cell and preclinical pharmacology | GH release through a GHRP-like receptor pathway; selectivity comparison in swine |
| Gobburu et al., 1999 | Healthy-volunteer intravenous infusion PK/PD | Brief GH-release episode; 2-hour terminal half-life estimate |
| Beck et al., 2014 | Phase 2 postoperative-ileus trial | No statistically significant difference in primary or secondary efficacy analyses |
Each row reports the endpoint actually studied. A result in one setting does not become a result for a different product, route or outcome.
Ipamorelin and GHRP-6 are different molecules that appear in GHRP-like secretagogue research. The foundational Ipamorelin paper compared their ability to release growth hormone in early experiments. Similar receptor context does not make their molecular identities, product labels or analytical records interchangeable.
CJC-1295 NO DAC and Sermorelin sit in a different research frame: GHRH analogues or fragments. Their core pathway is GHRH signalling, rather than the ghrelin-receptor pathway used to explain Ipamorelin. The “NO DAC” term identifies the CJC-1295 formulation and should never be attached to Ipamorelin.
Muscle Blend is a third category: a two-peptide product. Its label lists nominal 5mg CJC-1295 NO DAC plus nominal 5mg Ipamorelin. This gives a defined paired-pathway research question. It does not make a result from either single peptide a result for the blend, and its Janoshik COA #135350 does not verify this Ipamorelin 10mg vial.
| Listing | Research pathway | Key distinction |
|---|---|---|
| Ipamorelin 10mg | GHRP-like / ghrelin receptor | Single synthetic pentapeptide |
| GHRP-6 10mg | GHRP-like / ghrelin receptor | A different GHRP molecule |
| CJC-1295 NO DAC 10mg | GHRH analogue | NO DAC belongs to its CJC-1295 formulation |
| Sermorelin 10mg | GHRH fragment | A separate GHRH-pathway peptide |
| Muscle Blend | GHRH + GHRP-like | Nominal 5mg CJC-1295 NO DAC + 5mg Ipamorelin |
A comparison explains identity and pathway; it does not imply a combination recommendation or interchangeable evidence.
Ipamorelin is short enough to explain molecule by molecule. Its five building blocks are Aib, histidine, D-2-naphthylalanine, D-phenylalanine and a terminal lysine amide. The non-standard blocks and stereochemistry are part of the molecule’s identity; a name match alone is not an identity test.
PubChem lists the molecular formula C38H49N9O5, molecular weight 711.9 g/mol, CID 9831659, CAS 170851-70-4 and code NNC-26-0161. These identifiers help separate Ipamorelin from GHRP-6, CJC-1295 NO DAC and other short research peptides.
A structure diagram confirms what the named reference compound is. For a supplied vial, batch-specific identity and content reporting requires an analytical report tied to that batch. No LabDoc report is currently published for this listing.
Ipamorelin 10mg has no product-specific LabDoc report published. This listing has no linked report ID, LC-MS identity result, HPLC purity result, measured content or test date. The vial label displays 99% Purity.
A useful independent report identifies the material and batch, names the laboratory, records the method, then gives a result. LC-MS is used to check molecular identity by mass. HPLC separates material into peaks to report purity. A content measurement compares what was found with what the label claims.
The Peak Quality page contains available documentation. Muscle Blend Janoshik COA #135350 is documentation for the separate CJC-1295 NO DAC plus Ipamorelin blend. It does not constitute a test of this single-ingredient Ipamorelin 10mg vial, so this page does not use it as evidence for the vial.
Ipamorelin 10mg can be ordered online from Peak Peptides Australia when it is available. In-stock orders receive same-day dispatch from Victoria once payment is confirmed, use tracked Australia Post Express, and have a tracking number emailed.
This listing is a labelled 10mg research material supplied for in-vitro research only.
Australian and United States regulator material is clear that unapproved peptide products have not been evaluated by the TGA or FDA as approved medicines. The TGA’s 2026 advisory says unapproved peptide products have not been evaluated for safety, quality or effectiveness. The FDA identifies potential aggregation, impurity and immune-reaction concerns for compounded Ipamorelin acetate.
Step-by-step guide · About 10 minutes
Ipamorelin 10mg arrives as dry, freeze-dried powder. Reconstitution means adding bacteriostatic (BAC) water so the powder dissolves into a clear liquid with a known concentration. The PeptideDosages 10mg reference uses 3 mL, giving about 3.33 mg/mL. This illustrated handling guide takes about 10 minutes: prepare clean supplies, let water run down the glass, swirl gently, check clarity, then label and refrigerate the vial.
The dry vial’s total remains 10mg whichever water volume is used. Water changes concentration: 1 mL makes 10 mg/mL, 2 mL makes 5 mg/mL and 3 mL makes about 3.33 mg/mL. The PeptideDosages 10mg reference uses 3 mL.
At the 3 mL reference mix, 1 U-100 unit is 0.01 mL and holds about 0.033 mg, or 33 mcg. Therefore 30 units is 0.30 mL and holds about 1 mg. The formula is units = amount wanted ÷ strength per mL × 100.
| BAC water added | Strength | 1 unit holds | Units for 1 mg | Whole vial |
|---|---|---|---|---|
| 1 mL | 10 mg/mL | 0.1 mg (100 mcg) | 10 units | 100 units |
| 2 mL | 5 mg/mL | 0.05 mg (50 mcg) | 20 units | 200 units |
| 3 mL | 3.33 mg/mL | 0.033 mg (33.33 mcg) | 30 units | 300 units |
3 mL is highlighted because it gives the simplest numbers.
| Amount | Units on a U-100 syringe | Volume |
|---|---|---|
| 0.25 mg | 7.5 units | 0.075 mL |
| 0.5 mg | 15 units | 0.15 mL |
| 1 mg | 30 units | 0.3 mL |
| 2 mg | 60 units | 0.6 mL |
Set out the Ipamorelin 10mg vial, BAC water, a new 1 mL U-100 syringe, alcohol swabs and a sharps container on a clean surface. Check the vial label and powder before starting. If it has been chilled, allow the vial to reach room temperature before handling it.
Remove the plastic cap from the Ipamorelin vial and the BAC water vial. Wipe each rubber stopper with a fresh alcohol swab. Leave both stoppers to air-dry for about 30 seconds, and avoid touching the cleaned surface afterwards.
Use the clean U-100 syringe to draw the selected total volume of BAC water. A 1 mL U-100 syringe holds 100 units, so the 3 mL reference mix takes three 1 mL fills. Keep the selected final volume consistent so the chart concentration remains correct.
Place the needle through the Ipamorelin stopper at an angle so the tip rests against the inside wall. Press the plunger slowly and let the liquid run down the glass. Avoid directing a hard stream onto the dry powder. Repeat until the chosen total volume is in the vial.
Gently swirl the vial in slow circles or roll it between your fingers. A little undissolved powder can remain at first. Give it time to dissolve rather than forcing the process. Continue gently until the solution becomes clear.
Do not shake the vial. Shaking creates foam and bubbles, which makes the liquid harder to inspect and can be rough on a dissolved peptide. If foam appears, stand the vial upright and let the bubbles settle before checking the liquid again.
Hold the vial up to good light. A fully dissolved solution looks clear and has no visible powder, flecks or cloudiness. If material remains at the bottom, let it stand for 5–10 minutes and swirl again. Do not treat a cloudy or particulate solution as fully dissolved.
Write the preparation date and concentration on the vial. For the 3 mL reference mix, record about 3.33 mg/mL. Store it upright at 2–8 °C, protected from light. The illustrated BAC-water convention uses about 4 weeks and does not freeze the mixed vial.
| Form | Where to keep it | Handling period |
|---|---|---|
| Lyophilised powder | Fridge, 2–8 °C, protected from light | PeptideDosages lists refrigeration; keep at 2–8 °C and use within about 4 weeks (28 days). |
| Lyophilised powder | Freezer, −20 °C | Listed as an alternative storage condition by PeptideDosages |
| Mixed with BAC water | Fridge, 2–8 °C, upright and dark | Within about 4 weeks (28 days) |
| Mixed with BAC water | Freezer | Do not freeze the mixed vial |
Light and heat can change peptide preparations. Keep the vial upright in a closed container rather than in the refrigerator door.
Ipamorelin is a synthetic pentapeptide studied as a growth-hormone secretagogue. It acts at the growth-hormone secretagogue receptor, also called the ghrelin receptor, and prompts release of growth hormone rather than supplying growth hormone itself.
Ipamorelin 10mg is used in research on ghrelin-receptor signalling, pituitary growth-hormone release and related pharmacology. It is not evidence that this material builds muscle, improves sleep, speeds recovery, reduces fat or treats a health condition.
Ipamorelin is studied as an agonist at the growth-hormone secretagogue receptor. In early pharmacology, it stimulated pituitary growth-hormone release through a GHRP-like receptor pathway. The pathway is distinct from the GHRH-receptor pathway studied with Sermorelin and CJC-1295 NO DAC.
No. Ipamorelin is a secretagogue, meaning it prompts a signalling pathway associated with release of the body’s own growth hormone. Growth hormone medicines supply growth hormone itself. The names describe different molecules and different research questions.
The foundational study found growth-hormone release in pituitary-cell and preclinical experiments. A 1999 healthy-volunteer infusion study measured a short growth-hormone response. A Phase 2 postoperative-ileus trial did not show statistically significant benefit in its primary or secondary efficacy analyses.
In the 1999 pharmacokinetic study, healthy men received a 15-minute intravenous infusion. Growth hormone rose in one brief episode, peaking at 0.67 hours. The investigators estimated a 2-hour terminal half-life for Ipamorelin in that study setting.
The bowel-surgery trial recorded treatment-emergent adverse events in both groups: 87.5% with Ipamorelin and 94.8% with placebo. FDA identifies potential immune-reaction risks from aggregation or peptide impurities in compounded Ipamorelin acetate and lacks sufficient route-specific safety information for certain other injectable routes.
The published estimate is a 2-hour terminal half-life from a 1999 study in healthy male volunteers receiving a 15-minute intravenous infusion.
No. Both appear in GHRP-like growth-hormone-secretagogue research, but they are different molecules. The 1998 study compared them directly in early pharmacology work. Ipamorelin is a five-building-block peptide with its own molecular identity and CAS number.
Ipamorelin is researched through a GHRP-like or ghrelin-receptor pathway. CJC-1295 NO DAC is listed as a modified GHRH analogue. They are distinct molecules with different receptor contexts, product labels and evidence, so findings for one do not verify the other.
Ipamorelin is a GHSR or ghrelin-receptor research peptide. Sermorelin is a GHRH fragment. Both are discussed around growth-hormone signalling and act through different receptor pathways.
Muscle Blend is a separate two-peptide listing containing nominal 5mg CJC-1295 NO DAC plus nominal 5mg Ipamorelin. It is not a second name for Ipamorelin 10mg. Its composition creates a paired signalling research question, not proof of an outcome from either product.
No. Ipamorelin is not an FDA-approved medicine and it is not an approved medicine in Australia. The TGA states that unapproved peptide products have not been evaluated by the agency for safety, quality or effectiveness.
Yes. The 2026 World Anti-Doping Agency Prohibited List names Ipamorelin under growth-hormone secretagogues and their mimetics in section S2.2.4. That category is prohibited at all times, both in and out of competition.
Ipamorelin 10mg can be ordered online from Peak Peptides Australia when it is available. In-stock orders receive same-day dispatch from Victoria once payment is confirmed, travel by tracked Australia Post Express, and have a tracking number emailed. It is supplied for in-vitro research only.
In-stock orders receive same-day dispatch from Victoria once payment is confirmed. They travel with tracked Australia Post Express, and a tracking number is emailed. Carrier transit time depends on the destination and Australia Post’s network.
Check identity and batch-specific analytical evidence. An identity method such as LC-MS, a purity method such as HPLC, tested content, report date and traceable supplier details are useful. This listing has no product-specific LabDoc report published.
No product-specific LabDoc report is published for Ipamorelin 10mg. The vial label reads 99% Purity. Muscle Blend Janoshik COA #135350 covers a different blend.
The 10mg label states the total listed amount in the vial before liquid is added. It is not a concentration. Concentration comes from dividing that amount by the final measured volume; the BAC water chart shows the arithmetic for 1, 2 and 3 mL mixes.
The PeptideDosages 10mg reference uses 3 mL of BAC water, producing about 3.33 mg/mL. The chart also shows 1 mL at 10 mg/mL and 2 mL at 5 mg/mL. Adding more water changes concentration, not the 10mg total.
It depends on the final volume. At 3 mL in a 10mg vial, the strength is about 3.33 mg/mL and 1 mg is 30 units on a U-100 syringe. At 2 mL, 1 mg is 20 units; at 1 mL, it is 10 units.
With 3 mL added to a 10mg vial, 10 U-100 units equals 0.1 mL and holds about 0.33 mg. With 2 mL added, 10 units holds 0.5 mg. With 1 mL added, 10 units holds 1 mg.
The photo guide shows the basic laboratory handling sequence: clean the stoppers, draw BAC water, let it run slowly down the vial wall, then swirl instead of shaking. The liquid should be clear before it is labelled and refrigerated.
Do not use tap or distilled water. Bacteriostatic water contains 0.9% benzyl alcohol, while plain sterile water has no preservative. The PeptideDosages reference uses BAC water for its 10mg mixing arithmetic; follow the handling requirements of the exact research method.
Allow the vial to stand for 5–10 minutes, then swirl gently again. Do not shake it. The finished liquid should look completely clear, without visible powder, flecks or cloudiness. Material that stays cloudy or visibly particulate should not be treated as fully dissolved.
No. The visual preparation guide treats a clear, colourless solution with no visible powder or flecks as fully dissolved. Cloudiness, particles or powder remaining at the bottom means the dissolution check has not been passed.
The illustrated BAC-water guide uses about 4 weeks at 2–8 °C as its preparation convention. PeptideDosages states that mixed material should be refrigerated. Once mixed with BAC water, keep it upright at 2–8 °C, away from light, use it within about 4 weeks (28 days) and never freeze it. Write the date and strength on the vial.
The PeptideDosages 10mg reference lists 2–8 °C refrigeration for lyophilised material and −20 °C freezing as another storage condition. Keep the unopened vial in the fridge at 2–8 °C, protected from light, or at −20 °C for long-term storage.
No. The photo guide directs mixed material to be kept upright at 2–8 °C and not frozen. Freezing and thawing a peptide solution can change its physical state, so the illustrated handling sequence keeps it refrigerated rather than frozen.
A useful certificate of analysis identifies the tested material and batch, then records the methods and results for identity, purity and content. For example, LC-MS supports identity and HPLC supports a purity result. A COA for another product does not verify Ipamorelin 10mg.
Scientific background reference
Research references
Science sections summarise the published studies listed above. Test results for this product come from its own lab report.